Actuate Therapeutics Reports Positive Biomarker and Machine Learning Data from Phase 2 Elraglusib Trial in First-Line Treatment of Metastatic Pancreatic Cancer at ASCO
Phase 2 highlights robust biomarker identification and survival correlations in first-line metastatic…
Medidata Debuts Protocol Optimization at ASCO, Leveraging AI to Transform the Study Experience
New solution improves protocol design, reduces patient- and site-burden, accelerates recruitment, and…
